Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors), KRAS G12S inhibitors(KRAS G12S inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Jenthera Therapeutics, Inc.Startup |
Active Organization Jenthera Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | CA | Jenthera Therapeutics, Inc.Startup | 11 Aug 2024 |